[Anticoagulation and platelet inhibition - dosing recommendations at the beginning and the end of treatment]

Related Experiment Video

Updated: Jun 30, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

Boris T Ivandic1, Alexandra Zankl, Hugo A Katus

  • 1Abteilung Innere Medizin III, Medizinische Klinik der Universität Heidelberg. Boris.Ivandic@med.uni-heidelberg.de

Therapeutische Umschau. Revue Therapeutique
|September 30, 2008
PubMed

Insights

Managing anticoagulant and anti-platelet therapies is crucial for cardiovascular medicine. Understanding drug actions and risks is key, especially with new agents and pharmacogenomic considerations.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Anticoagulants and anti-platelet drugs are vital in cardiovascular medicine.
  • Managing the initiation, termination, or discontinuation of these therapies is critical.
  • Novel anti-thrombotic drugs with diverse mechanisms are emerging.

Purpose:

  • To review clinically relevant principles of anti-thrombotic therapy management.
  • To discuss the assessment of individual thrombotic and bleeding risks.
  • To highlight the importance of pharmacodynamics, pharmacokinetics, and pharmacogenomics for new drugs.

Summary:

  • This review covers essential principles for managing anticoagulant and anti-platelet therapies.
  • It emphasizes understanding drug mechanisms, pharmacodynamics, and pharmacokinetics.
  • Individual thrombotic and bleeding risk assessment, alongside pharmacogenomics, is highlighted for optimizing treatment with novel agents.

Impact:

  • Provides guidance for clinicians managing anti-thrombotic therapies.
  • Informs the safe and effective use of current and upcoming anti-thrombotic drugs.
  • Underscores the growing role of personalized medicine through pharmacogenomics in cardiovascular care.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...